Gung ho: Al­ny­lam lands his­toric FDA OK on patisir­an, revving up the first glob­al roll­out for an RNAi break­through

7 years ago
Pharma

Af­ter mixed pipeline up­dates, Re­genXBio to raise $175M in of­fer­ing; Bio­Elec­tron clos­es $40M to prep late-stage ...

7 years ago
News Briefing

PARP in­hibitors for ALS? Penn re­searchers post promis­ing finds in brain dis­ease

7 years ago
Discovery

Mer­ck vet Thomas Can­nell takes the reins at Sesen Bio; Post-tur­bu­lence, Rock­well Med­ical ap­points new CEO

7 years ago
Peer Review

Trump ad­min­is­tra­tion sinks teeth in­to par­ing down drug prices, on 5 key points

7 years ago
Pharma

Pfiz­er, No­var­tis jump in­to an $84M de­vel­op­ment round for UK can­cer drug stars at Ar­tios

7 years ago
Financing

Chi­na reg­u­la­tors of­fer VIP treat­ment for 48 over­seas drugs they're ready to hus­tle up with ac­cel­er­at­ed re­views

7 years ago
China
Pharma

In back-to-back tri­al dis­as­ters, Gem­phire now says it shut­tered a tri­al af­ter see­ing pa­tients' fat­ty liv­er dis­ease ...

7 years ago
R&D

Astel­las grabs a biotech tod­dler in $109M buy­out deal for a glau­co­ma gene ther­a­py pro­gram

7 years ago
Deals
Cell/Gene Tx

Lig­and ac­quires Ver­nalis at bar­gain price of $43M; Pfiz­er, No­vo back $60M round for dwarfism biotech

7 years ago
News Briefing

Once a multi­bil­lion dol­lar com­pa­ny, Ova­Science ends a pen­ny­s­tock ve­hi­cle for Mil­len­do's re­verse merg­er

7 years ago
Deals

Bio­gen's high-stakes Alzheimer's gam­ble is be­ing roast­ed by the ex­perts. Is the amy­loid be­ta the­o­ry dead?

7 years ago
R&D
Pharma

That BLA lit­tle Am­pio promised? That’s not go­ing any­where as FDA slap-down trig­gers an ug­ly rout

7 years ago
R&D

Tout­ing its man­u­fac­tur­ing strengths, Tot Bio­pharm rais­es $102M mega-round to ramp up can­cer R&D

7 years ago
Financing
China

FDA ap­proves first gener­ic drug to re­ceive CGT des­ig­na­tion

7 years ago
Pharma

Sarep­ta all-in on gene ther­a­py pipeline, adding 3 CNS treat­ments in $30M Lac­er­ta deal

7 years ago
Pharma

Tap­ping Chi­nese in­vestors, Apex­i­gen clos­es $73M for 8 tri­als in I/O

7 years ago
Financing
Startups

Ky­owa Kirin gets some added love from the FDA, win­ning their sec­ond drug OK in 4 months

7 years ago
Pharma

Paratek clears one last big hur­dle on the way to an FDA mar­ket­ing de­ci­sion for an­tibi­ot­ic

7 years ago
R&D

In­sid­er trad­ing in Wash­ing­ton: NY Con­gress­man in­dict­ed for shar­ing in­side biotech tips ahead of mas­sive tri­al fail­ure

7 years ago
People

BeiGene takes a hit af­ter his­toric $903M Hong Kong IPO with neg­a­tive biotech sen­ti­ment

7 years ago
Financing
China

Cell­tri­on re­ceives Form 483 for trou­bled Ko­re­an site

7 years ago
Pharma

Prof­its sink­ing, My­lan looks to strate­gic al­ter­na­tives; No­vo posts de­press­ing Q2

7 years ago
News Briefing

Re­genxBio ral­ly fades fast af­ter biotech re­ports set­backs, hos­pi­tal­iza­tion in gene ther­a­py study

7 years ago
R&D
First page Previous page 1019102010211022102310241025 Next page Last page
A service from the Financial Times